REFERENCES
- Muder RR, Yu VL, Duwmer JS, Vinson C, Lumish RM. Infections caused by Pseudomonas maltophilia. Arch Inter Med 1987; 147: 1672–74.
- Morrison AJ, Hoffmann KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a University hospital. J Clin Microbiol 1986; 24: 52–55.
- Aoun M, van der Auwera, Devleeshouwer C, et al. Bacteraemia caused by non-aeuroginosa Pseudomonas species in a cancer centre. J Hosp Infect 1992; 22: 307–16.
- Meunier F. Infections in patients with acute leukemia and lymphoma. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 4th edn. New York: Churchill Livingstone, 1995; 2675–86.
- Spencer RC. The emergence of epidemic multiple antibiotic resistant Stenotrophomonas (Xanthomonas) maltophilia and Bulkholderia (Pseudomonas) cepacia. J Hosp Infect 1995; 30 (Supp): 453-64.
- Elting L, Khardori N, Bodey GP, Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia. A case control study of predisposing factors. Infect Control Hosp Epidemiol 1990; 11: 134–8.
- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disc susceptibility tests, 5th edn. Approved standard. NCCLS document M2-A5 Villanova, PA: NCCLS, 1993.
- Edwards J, Turner P. Laboratory data which differentiate meropenem and imipenem. Scand J Infect Dis 1995; Suppl 96: 5-10.
- Drusano G. Meropenem: laboratory and clinical data. Clin Microbiol Infect 1997; (suppl 4) 3: 51-9.
- Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11: 57–80.
- Vartivarian SE, Papadakis KA, Palacious JA, Manning JT, Anaissie EJ. Mucocutanious and soft tissue infections caused by Xanthomonas maltophilia, a new spectrum. Arch Intern Med 1994; 121: 969–73.
- Sanyal SC, Mokaddas EM, Gang RK, Bang RL. Microbiology of septicaemia in burn patients. Ann Burns Fire Disasters 1998; XI: 19-22.
- Livermore D. Multiresistance and `superbugs'. Communicable Dis Public Health 1998; 1: 74–76.
- Saino Y, Inoue M, Mitsuhashi S. Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN 12873. Antimicrob Agents Chemother 1984; 25: 362–65.
- Pradahananga SL, Rowling PJ, Simpson IN, Payne DJ. Sensitivity of L2-type β-lactamases from Stenotrophomonas maltophilia to serine active site β-lactamase inhibitors. J Antimicrob Chemother 1996; 37: 394–96.
- Paton R, Miles RS, Amyes SGB. Biochemical proper-ties of inducible β-lactamase produced from Xanthomonas maltophilia. Antimicrob Agents Chemother 1994; 38: 2143–9.
- Hupkova M, Blahova J, Kratikova J, Kremery V. Transferable resistance to β-lactams in a nosocomial strain of Xanthomonas maltophilia. Antimicrob Agents Chemother 1995; 39: 1011–2.
- Wilcox MH, Winstanley TG, Spencer RC. Outer mem-brane protein profiles of Xanthomonas maltophilia isolates displaying temperature-dependent susceptibility to gentamicin. J Antimicrob Chemother 1994; 33: 663–6.
- Wayne SJ, Boquest AL, Geddes JE, Tosolini FA. The antibiotic susceptibilities of Xanthomonas maltophilia and their relation to clinical management. Pathology 1994; 26: 321–4.
- Manian FA, Meyer L, Jenne J, Owen A, Taff T. Loss of antimicrobial susceptibility in aerobic Gram-negative bacilli repeatedly isolated from patients in intensive care units. Infect Control Hosp Epidemiol 1996; 17: 222–6.